Abstract
Galantamine hydrogen bromide (HBr) is a competitive and reversible inhibitor of acetylcholinesterase. Because of its cholinergic nicotinic mechanism of action, galantamine HBr was hypothesized to have therapeutic activity in the treatment of attention-deficit/hyperactivity disorder (ADHD). We conducted a 12-week, double-blind, placebo-controlled, randomized clinical trial using daily doses of up to 24 mg/d of galantamine HBr in the treatment of adults who met full Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for ADHD with childhood-onset and persistent adult symptoms. All analyses were intention to treat with the last observation carried forward for subjects who did not complete the full study schedule. The mean daily doses at week 12 were 19.8 +/- 6.4 mg for galantamine HBr and 21.8 +/- 4.6 mg for placebo (P = 0.3). There was no statistically or clinically significant greater reduction in ADHD symptoms in subjects treated with galantamine HBr relative to those receiving placebo (P = 0.5). Using last observation carried forward, 4 (22%) of 18 of patients receiving galantamine HBr were considered responders (much or very much improved on the Clinical Global Impression Improvement Scale and at le...Continue Reading
References
Jan 1, 1992·Psychopharmacology·G M JonesJ A Gray
Jan 1, 1984·Psychopharmacology·K Wesnes, D M Warburton
Jan 1, 1984·Psychopharmacology·S C Peeke, H V Peeke
Jun 1, 1995·Archives of General Psychiatry·T SpencerK Lapey
Feb 1, 1994·Journal of Clinical Psychopharmacology·E D LevinJ E Rose
May 20, 1998·The American Journal of Psychiatry·T SpencerL Seidman
Sep 6, 2001·Archives of General Psychiatry·T SpencerS K Bearman
Mar 3, 2004·The American Journal of Psychiatry·Jeffrey L CummingsWeiying Yuan
Oct 16, 2004·Journal of Consulting and Clinical Psychology·Joseph BiedermanStephen V Faraone
Citations
Oct 5, 2011·Psychopharmacology·Alexandra S PotterPaul A Newhouse
Aug 14, 2012·Current Psychiatry Reports·Nikki IvanchakGregory A Jicha
Feb 12, 2011·Patient Preference and Adherence·Kate Van BruntJoseph A Johnston
Aug 30, 2011·CNS Drugs·Paramala J SantoshMyooran Canagaratnam
Jun 28, 2014·International Journal of High Risk Behaviors & Addiction·Nour-Mohammad Bakhshani
Oct 29, 2014·CNS Drugs·Alexandra S PotterMegan Shipman
Dec 24, 2015·Expert Review of Neurotherapeutics·Massimiliano BuoliWiepke Cahn
Jul 8, 2009·The International Journal of Neuropsychopharmacology·Agnes MészárosIstván Bitter
Aug 12, 2009·Neuroscience and Biobehavioral Reviews·Peter DomeZoltan Rihmer
Oct 2, 2009·Journal of Attention Disorders·Thomas J SpencerDouglas K Kelsey
May 22, 2019·Expert Opinion on Pharmacotherapy·Giulio PerugiPietro De Rossi
Jun 18, 2017·European Journal of Clinical Pharmacology·Pål GjerdenLars Slørdal
Aug 22, 2017·Frontiers in Aging Neuroscience·Brandy L CallahanSandra E Black
Oct 1, 2011·Expert Review of Neurotherapeutics·Timothy E WilensJefferson Prince
Apr 12, 2018·Current Medicinal Chemistry·Manuela M LaikowskiSidnei Moura